|Dr. Andrew Cheng||Pres, CEO & Director||747.05k||N/A||1967|
|Dr. Jonathan M. Young||Co-Founder, EVP & COO||600k||N/A||1970|
|Mr. Timothy Rolph||Co-Founder & Chief Scientific Officer||600k||N/A||1954|
|Mr. William R. White J.D.||Exec. VP, CFO & Head of Corp. Devel.||494.3k||N/A||1973|
|Ms. Kitty Yale||Exec. VP & Chief Devel. Officer||N/A||N/A||1972|
|Mr. John J. Schembri||VP of Fin. & Controller||N/A||N/A||1962|
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.
Akero Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2020 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.